A phase II study of nivolumab (N) plus ipilimumab (I) in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC).
Jochen H. Lorch(Northwestern University), David A. Barbie(Dana-Farber Cancer Institute), Jonathan D. Schoenfeld(Brigham and Women's Hospital), Laura A. Goguen(Brigham and Women's Hospital), Glenn J. Hanna(Dana-Farber Cancer Institute), Matthew I. Kim(Brigham and Women's Hospital), Darren Stanizzi(Dana-Farber Cancer Institute), Matthew A. Nehs(Brigham and Women's Hospital), Ellen Marqusee(Brigham and Women's Hospital), Sara Ahmadi(Brigham and Women's Hospital), Ravindra Uppaluri(Brigham and Women's Hospital), Ethan Harris(University of Chicago), Justine A. Barletta(Brigham and Women's Hospital), Roy B. Tishler(Dana-Farber Cancer Institute), Alec Kacew(Hospital of the University of Pennsylvania), Danielle N. Margalit(Harvard University), Robert I. Haddad(Georgetown University), Azad Jabiev(Baystate Medical Center), Erik K. Alexander(Mass General Brigham), Meredith J. Sorensen(Dartmouth–Hitchcock Medical Center)
Cited by 65
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
|Nature|2009|4.2k
2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum
|Thyroid|2017|2.7k
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
|Cell|2018|2k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k